ClinicalTrials.gg
RecruitingNCT06186414Updated Jan 15, 2025

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

A Phase 1 interventional study of SIM0237 and SIM0237 and BCG in Non-Muscle-Invasive Bladder Cancer (NMIBC), sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Recruiting at 14 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-15.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms — 6 open to participants now, 12 under way, 5 of them phase 3. BCG Vaccine · Non-Muscle Invasive Bladder Neoplasms.

Planned enrollment
10th of 17
152 · median 160
Started
2024
the only one that year
Primary completion
2027-01
later than 6 of 11 live
Registered
11th of 17
by date

Among the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, this one is the 10th largest by planned enrollment, is the only one that started in 2024, reaches primary completion later than 6 of the 11 other live ones, and was the 11th registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

6 of the 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About BCG Vaccine

BCG Vaccine: first FDA approval 1989 (N/A). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing BCG Vaccine in Non-Muscle Invasive Bladder Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)

Read the detailed description

The study starts with a dose escalation part followed by a dose expansion part. The primary objective of the dose escalation part is to evaluate the safety and tolerability of SIM0237 alone or in combination with BCG, and determine the recommended dose(s) (RD). The primary objective of the dose expansion part is to evaluate the preliminary efficacy of SIM0237 alone or in combination with BCG.

03

Conditions studied

  • Non-Muscle-Invasive Bladder Cancer (NMIBC)

Keywords

  • NMIBC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written .
  • ≥ 18 years of age, male or female.
    • confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease. Histologic confirmation of urothelial carcinoma (mixed histology tumors allowed if urothelial histology is predominant histology).
  • Dose escalation phase: BCG-unresponsive high-risk NMIBC.
  • Dose expansion phase: a) Cohorts 1 and 3: BCG-unresponsive CIS (with or without Ta or T1 disease); b) Cohort 2 and 4: BCG-unresponsive high-risk Ta or T1 disease.
  • Absence of resectable disease after transurethral resection (TURBT) procedures [residual carcinoma in situ (CIS) acceptable]. patients with T1 tumors must undergo repeat resection and pathological test if initial pathological test sample did not include muscularis propria, to ensure the inclusive of muscularis propria and the absence of invasive tumor.
  • Not suitable for or unwilling to undergo radical cystectomy.
  • performance status of 0, 1or 2.
  • ≥ 2 years.
  • Adequate hematologic and organ function.
  • Women of (WOCBP) must have a negative serum pregnancy test. WOCBP and male subjects agree to use adequate .
  • Tumor tissue (archival or fresh) for biomarker analysis.

Exclusion criteria

Exclusion Criteria:

    • Subjects received TURBT or other surgical treatment for bladder lesions or pelvic radiotherapy or interventional therapy within 2 weeks prior to the first dose.
  • Previous treatment with: a) IL-15 or IL-2; b) (such as anti-PD-1 or PD-L1 antibodies), ADCs, chemotherapies, oncolytic viruses, BCG or other anti-tumor treatments, unless there is clear evidence of disease persistence/recurrence/progression after the above treatments and beyond 4 weeks prior to the first dose; c) Chinese herbal medicine treatment beyond 2 weeks prior to the first dose is allowed; d) A single immediate instillation of chemotherapy within 4 weeks prior to the first dose is allowed; e) intravesical instillation of mucosal protective agents (e.g., sodium hyaluronate) are allowed.
  • Subject is participating in an drug or investigational device study.
  • Subjects have not recovered from AEs caused by previous anti-tumor treatment.
  • History/evidence of prior muscle-invasive, locally advanced, bladder cancer or upper urinary tract (kidney, renal pelvis, ureter) and prostatic urethral tumors; or evidence of Ta/T1/CIS urothelial transitional cell carcinoma outside the bladder (urethra, ureter, renal pelvis) during the screening period.
  • Patients with other within 5 years before the first dose.
  • Any active infection or urinary tract infection requiring systemic treatment by intravenous infusion within 2 weeks before the first dose.
  • Subjects with cardiovascular disease within 6 months before the first dose of study treatment.
  • Known (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
  • Active or chronic or infection.
  • Known or suspected active diseases.
  • Concurrent use of any other anticancer therapy or chronic use of systemic at doses (more than 10 mg/day prednisone or equivalent).
  • History of pneumonitis or interstitial lung disease or severe obstructive pulmonary disease that requires oral or intravenous steroids to help recover.
  • Known to be allergic or intolerant to study drugs, monoclonal antibodies, ; or allergic or intolerant to BCG (only for subjects receiving combined BCG therapy)
  • Subjects discontinued prior BCG treatment due to AEs such as toxemia, systemic infection, or urinary incontinence (only for subjects receiving combined BCG therapy).
  • History of allogeneic organ transplantation or .
  • Any within 4 weeks before the first dose.
  • Known mental illness or substance abuse that would interfere with trial complies.
  • Subject is pregnant or lactating, or is expected to become pregnant or parent a child during the planned study period.
  • Other conditions that investigators consider inappropriate for inclusion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Dose escalation-mono

    BCG-unresponsive high-risk NMIBC, receiving SIM0237 monotherapy intravesically.

    Drug: SIM0237

  • Experimental
    Dose escalation-combo

    BCG-unresponsive high-risk NMIBC, receiving SIM0237 and BCG intravesically.

    Drug: SIM0237 and BCG

  • Experimental
    Dose expansion-Cohort 1

    BCG-unresponsive CIS, receiving SIM0237 monotherapy intravesically.

    Drug: SIM0237

  • Experimental
    Dose expansion-Cohort 3

    BCG-unresponsive CIS, receiving SIM0237 and BCG intravesically.

    Drug: SIM0237 and BCG

  • Experimental
    Dose expansion-Cohort 4

    BCG-unresponsive high-risk Ta or T1, receiving SIM0237 and BCG intravesically.

    Drug: SIM0237 and BCG

  • Experimental
    Dose expansion-Cohort 2

    BCG-unresponsive high-risk Ta or T1, receiving SIM0237 monotherapy intravesically.

    Drug: SIM0237

Interventions

  • DrugSIM0237

    Several dose levels of SIM0237 will be administered as a single agent for evaluation

  • DrugSIM0237 and BCG

    Drug page: BCG Vaccine

    Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

  • DrugSIM0237

    RD level of SIM0237 will be administered as a single agent for evaluation

  • DrugSIM0237 and BCG

    Drug page: BCG Vaccine

    RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

06

What researchers measure

Primary outcomes

  1. Dose escalation:Dose limited toxicity (DLT)

    Time frame: DLT observation period (up to 21 days)

  2. Dose escalation: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)

    Incidence and severity of adverse events (AEs) and serious adverse events(SAEs),and lab abnormalities

    Time frame: through study completion, an average of 5 years

  3. Dose expansion:Complete response (CR) rate at Month 3

    Complete response (CR) rate at of Cohort 1 and Cohort 3

    Time frame: through study completion, an average of 5 years

  4. Dose escalation: Percentage of participants experiencing AE related dose interruptions and dose delays, dose intensity

    Occurrence of AE related dose interruptions, dose delays and dose intensity

    Time frame: through study completion, an average of 5 years

07

Study locations

6 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 24 phase 1 interventional studies under Non-Muscle Invasive Bladder Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 61. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Jan 2, 2024
StartActual
Jan 23, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2030
Last update
Jan 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06186414
Collaborators
Shanghai Xianxiang Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Jan 23, 2024
Primary completion
Jan 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jan 15, 2025

Study contacts

Tammy Wu, Ph.D
Contact
wutao@zaiming.com
13671827233
Wei Xiong, Master
Contact
wei.xiong@zaiming.com
18252091329

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCG Vaccine

Start the discussion